An assessment of care pathways, not a new clinical trial
The work compares monitoring pathways with and without glycated albumin, using HbA1c as the reference marker. It takes the perspective of the Italian national health service and uses the EUnetHTA assessment framework.
The analysis combines a systematic literature review, economic evaluations and questionnaires gathering stakeholders’ perceptions. It therefore examines several dimensions: clinical outcomes, costs and the organisation of care. However, the abstract does not specify the number of studies included, their sample sizes or their follow-up durations.
A favourable signal whose significance remains difficult to assess
According to the authors, the review suggests that glycated albumin is better at identifying poor glycaemic control than HbA1c alone in this population. The abstract also mentions a reduction in adverse events, without specifying which events or providing their absolute frequency. It therefore does not allow a direct assessment of the clinical importance of this benefit.
The economic analysis estimates overall annual savings of 2.02% with the integration of glycated albumin. This result applies to the Italian context studied: it does not establish savings for the French healthcare system.
The professionals surveyed also give glycated albumin more favourable ratings for safety, effectiveness and the organisation of the care pathway. These perceptions complement the analysis but do not replace clinical outcomes measured in patients.
A potential complement, not an established replacement
The authors’ conclusion concerns the value of a complementary biomarker. It does not justify abandoning HbA1c or extending glycated albumin testing to everyone with diabetes.
The population studied is specific: people with type 2 diabetes and advanced chronic kidney disease. The dossier does not support extending these conclusions to people without kidney disease or to using this marker to optimise the health of someone without diabetes.
Limitations to keep in mind
Only the PubMed abstract was consulted. The quality and heterogeneity of the included studies, the economic assumptions and the details of adverse events cannot be verified from the dossier. Funding and conflicts of interest were not checked.
What we can take away
This assessment supports the potential value of glycated albumin as a complement to HbA1c in a well-defined clinical population. On its own, it is not enough to establish a change in practice.
Sources and provenance
- Rethinking glycemic monitoring: a HTA of glycated albumin for type 2 diabetes with stage IV-V CKD.
Source date: 2026-10-30.
Journal Article, Systematic Review · Résumé PubMed uniquement, texte intégral non consulté